Fine Mapping and Candidate Gene Analysis of Dravet Syndrome Modifier Loci on Mouse Chromosomes 7 and 8

Overview

Journal Mamm Genome

Specialty Genetics

Date 2024 Jun 11

PMID 38862622

Authors

Nicole A Hawkins

Nathan Speakes

Jennifer A Kearney

Affiliations

Soon will be listed here.

Abstract

Dravet syndrome is a developmental and epileptic encephalopathy (DEE) characterized by intractable seizures, comorbidities related to developmental, cognitive, and motor delays, and a high mortality burden due to sudden unexpected death in epilepsy (SUDEP). Most Dravet syndrome cases are attributed to SCN1A haploinsufficiency, with genetic modifiers and environmental factors influencing disease severity. Mouse models with heterozygous deletion of Scn1a recapitulate key features of Dravet syndrome, including seizures and premature mortality; however, severity varies depending on genetic background. Here, we refined two Dravet survival modifier (Dsm) loci, Dsm2 on chromosome 7 and Dsm3 on chromosome 8, using interval-specific congenic (ISC) mapping. Dsm2 was complex and encompassed at least two separate loci, while Dsm3 was refined to a single locus. Candidate modifier genes within these refined loci were prioritized based on brain expression, strain-dependent differences, and biological relevance to seizures or epilepsy. High priority candidate genes for Dsm2 include Nav2, Ptpn5, Ldha, Dbx1, Prmt3 and Slc6a5, while Dsm3 has a single high priority candidate, Psd3. This study underscores the complex genetic architecture underlying Dravet syndrome and provides insights into potential modifier genes that could influence disease severity and serve as novel therapeutic targets.

References

Villas N, Meskis M, Goodliffe S . Dravet syndrome: Characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017; 74:81-86. DOI: 10.1016/j.yebeh.2017.06.031. View

McLaren W, Gil L, Hunt S, Riat H, Ritchie G, Thormann A . The Ensembl Variant Effect Predictor. Genome Biol. 2016; 17(1):122. PMC: 4893825. DOI: 10.1186/s13059-016-0974-4. View

Feng T, Makiello P, Dunwoody B, Steckler F, Symonds J, Zuberi S . Long-term predictors of developmental outcome and disease burden in -positive Dravet syndrome. Brain Commun. 2024; 6(1):fcae004. PMC: 10789590. DOI: 10.1093/braincomms/fcae004. View

Baek J, Rubinstein M, Scheuer T, Trimmer J . Reciprocal changes in phosphorylation and methylation of mammalian brain sodium channels in response to seizures. J Biol Chem. 2014; 289(22):15363-73. PMC: 4140893. DOI: 10.1074/jbc.M114.562785. View

Niibori Y, Lee S, Minassian B, Hampson D . Sexually Divergent Mortality and Partial Phenotypic Rescue After Gene Therapy in a Mouse Model of Dravet Syndrome. Hum Gene Ther. 2019; 31(5-6):339-351. PMC: 7087406. DOI: 10.1089/hum.2019.225. View

Kearney J, Copeland-Hardin L, Duarte S, Zachwieja N, Eckart-Frank I, Hawkins N . Fine mapping and candidate gene analysis of a dravet syndrome modifier locus on mouse chromosome 11. Mamm Genome. 2022; 33(4):565-574. PMC: 9616761. DOI: 10.1007/s00335-022-09955-y. View

Sada N, Lee S, Katsu T, Otsuki T, Inoue T . Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015; 347(6228):1362-7. DOI: 10.1126/science.aaa1299. View

Kearney J . Genetic modifiers of neurological disease. Curr Opin Genet Dev. 2011; 21(3):349-53. PMC: 3105121. DOI: 10.1016/j.gde.2010.12.007. View

Osaka H, Ogiwara I, Mazaki E, Okamura N, Yamashita S, Iai M . Patients with a sodium channel alpha 1 gene mutation show wide phenotypic variation. Epilepsy Res. 2007; 75(1):46-51. DOI: 10.1016/j.eplepsyres.2007.03.018. View

10.

Morison I, Reeve A . A catalogue of imprinted genes and parent-of-origin effects in humans and animals. Hum Mol Genet. 1998; 7(10):1599-609. DOI: 10.1093/hmg/7.10.1599. View

11.

Hammer M, Ishii A, Johnstone L, Tchourbanov A, Lau B, Sprissler R . Rare variants of small effect size in neuronal excitability genes influence clinical outcome in Japanese cases of SCN1A truncation-positive Dravet syndrome. PLoS One. 2017; 12(7):e0180485. PMC: 5501540. DOI: 10.1371/journal.pone.0180485. View

12.

Nabbout R, Gennaro E, Dalla Bernardina B, Dulac O, Madia F, Bertini E . Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology. 2003; 60(12):1961-7. DOI: 10.1212/01.wnl.0000069463.41870.2f. View

13.

Kim H, Jung H, Jung H, Kwon S, Ko J, Um J . The small GTPase ARF6 regulates GABAergic synapse development. Mol Brain. 2020; 13(1):2. PMC: 6945580. DOI: 10.1186/s13041-019-0543-3. View

14.

Kalume F, Westenbroek R, Cheah C, Yu F, Oakley J, Scheuer T . Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Invest. 2013; 123(4):1798-808. PMC: 3613924. DOI: 10.1172/JCI66220. View

15.

Guerrini R, Cellini E, Mei D, Metitieri T, Petrelli C, Pucatti D . Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene. Epilepsia. 2011; 51(12):2474-7. DOI: 10.1111/j.1528-1167.2010.02790.x. View

16.

Rees M, Harvey K, Pearce B, Chung S, Duguid I, Thomas P . Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet. 2006; 38(7):801-6. PMC: 3204411. DOI: 10.1038/ng1814. View

17.

Yu F, Mantegazza M, Westenbroek R, Robbins C, Kalume F, Burton K . Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006; 9(9):1142-9. DOI: 10.1038/nn1754. View

18.

Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S . Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 2011; 52 Suppl 2:50-4. DOI: 10.1111/j.1528-1167.2011.03002.x. View

19.

Yordanova I, Todorov T, Dimova P, Hristova D, Tincheva R, Litvinenko I . One novel Dravet syndrome causing mutation and one recurrent MAE causing mutation in SCN1A gene. Neurosci Lett. 2011; 494(2):180-3. DOI: 10.1016/j.neulet.2011.03.008. View

20.

Goldberg-Stern H, Aharoni S, Afawi Z, Bennett O, Appenzeller S, Pendziwiat M . Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus. J Child Neurol. 2013; 29(2):221-6. DOI: 10.1177/0883073813509016. View